Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a significant decline in short interest in September. As of September 30th, there was short interest totalling 223,168 shares, a decline of 22.2% from the September 15th total of 286,805 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 83,996 shares, the days-to-cover ratio is presently 2.7 days.
Hemispherx BioPharma (NYSE:HEB) opened at 1.10 on Wednesday. Hemispherx BioPharma has a one year low of $0.72 and a one year high of $2.64. The stock’s market cap is $22.82 million. The stock’s 50 day moving average price is $1.29 and its 200-day moving average price is $1.52.
Hemispherx BioPharma (NYSE:HEB) last announced its earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. During the same period last year, the business earned ($0.02) earnings per share.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.